Tips for Pharmaceutical Manufacturing Scale-Up & Tech Transfer

In a recent scale-up scenario, a pharmaceutical company found discrepancies in product quality attributes between PPQ runs during scale-up and previous batches. Specific symptoms included inconsistent potency results, variability in…

The symptoms of regulatory non-compliance can often appear subtly at first. In this scenario, the manufacturing facility noted the following signals after a recent scale-up:Click to read the full article.

Identifying symptoms early is crucial in handling equipment changes during scale-up. Common signals that may indicate issues include:Click to read the full article.

Identifying potential regulatory complications during equipment changes involves close observation of specific symptoms or signals both on the production floor and in laboratory analysis. Common indicators of issues include:Click to…

The initial identification of potential stability issues typically comes from various signals, including:Click to read the full article.

Assessing the Effects of Packaging Scale-Up Changes on Regulatory Filings In pharmaceutical manufacturing, the transition from pilot to commercial-scale production often requires careful consideration of the regulatory landscape, particularly in…

Recognizing symptoms indicative of issues arising from packaging scale-up changes is crucial in early detection. Symptoms may vary based on the adjustments made and could include:Click to read the full…

Identifying the early signs of issues during scale-up is crucial for ensuring that deviations do not lead to significant regulatory non-compliance. Here are some common symptoms you might encounter:Click to…

Before delving into mitigating actions, it is vital to recognize the symptoms indicating potential issues with scale-up documentation. Possible signals include:Click to read the full article.

During routine batch release processes, the quality assurance (QA) team noticed deviations in cleaning validation results compared to established parameters. Specifically, residual cleaning agent concentrations were found to exceed predetermined…

The symptoms of an inadequate cleaning validation during scale-up often manifest in several tangible forms. In a recent scenario involving a mid-sized biopharmaceutical company, the following signals were detected:Click to…

Recognizing the signals that arise due to changes in raw materials is critical to addressing potential regulatory implications. Here are common symptoms that suggest raw material changes could be affecting…